Skip to content

ALNY · ALNYLAM PHARMACEUTICALS, INC.

22 filings

10-K

ALNY 10-K Annual Reports

ALNYLAM PHARMACEUTICALS, INC. - 22 annual reports

Filing record · 2016–202610-K1110-Q328-K121

2025
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2025
Alnylam Pharmaceuticals reported its first full year of GAAP profitability in 2025, with total revenues of $3.71 billion (up 65% year over year) and net income of $313.7 million, compared with a net loss of $278.2 million in 2024. The growth was driven overwhelmingly by AMVUTTRA, whose net product revenue rose 138% to $2.31 billion following FDA approval for ATTR cardiomyopathy (ATTR-CM) in March 2025. Total net product revenues reached $2.99 billion, while collaboration revenue of $553 million included a one-time $300 million Roche milestone that management expects will not recur, so collaboration revenue is guided lower in 2026. Investors should weigh the quality of earnings against several headwinds. Cost of goods sold rose to 22.7% of product revenue from 18.6%, because royalties owed to Sanofi on AMVUTTRA escalate in tiers up to 30%, and management expects that ratio to rise further in 2026. Operating expenses grew 32% to $3.21 billion, and the company carries about $2.5 billion of debt-like obligations, including $1.01 billion of convertible notes and roughly $2.95 billion of liabilities tied to sales of future royalties and development funding. The balance sheet is stronger, with $2.91 billion in cash and marketable securities and stockholders' equity turning positive at $789 million, but a $1.15 billion repurchase of 2027 Notes and a new $500 million revolver show active liability management. The 2030 'Alnylam 2030' goals call for 25%+ revenue CAGR and roughly 30% non-GAAP operating margin. Key risk items include Leqvio generic (Paragraph IV) challenge, competition from lower-priced oral TTR therapies, pricing and healthcare reform exposure, a U.S. Attorney's Office subpoena on government price reporting, and continued reliance on third-party manufacturers and collaborators. Pipeline catalysts include nucresiran Phase 3 trials, the ZENITH outcomes trial for zilebesiran, and the HHT Phase 2 program for ALN-6400.
Feb 12, 2026
2024
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2024
Alnylam Pharmaceuticals (ALNY) enters 2025 as a commercial-stage RNAi company with five approved products and a stated goal of becoming a self-sustainable, top-tier biotech by the end of 2025 under its Alnylam P5x25 strategy. FY2024 total revenues rose 23% to $2.25 billion, driven by net product revenues of $1.65 billion (up 33%), led by AMVUTTRA at $970.5 million (up 74%). ONPATTRO declined 29% to $252.9 million as patients switched to AMVUTTRA, while GIVLAARI ($255.9 million) and OXLUMO ($167.1 million) grew. Collaboration revenue fell 7% to $510.2 million, largely because of a one-time Roche license recognition in 2023, and royalty revenue more than doubled to $91.8 million on Leqvio sales by Novartis. Profitability improved sharply but the company remains unprofitable. The net loss narrowed to $278.2 million from $440.2 million, helped by a $99.2 million tax benefit from releasing a Swiss valuation allowance, and operating loss narrowed to $176.9 million. Operating cash flow was roughly breakeven at negative $8.3 million, and cash, equivalents and marketable securities reached $2.69 billion against $1.04 billion of 1% convertible notes due 2027 and a $1.45 billion liability related to the Blackstone royalty sale. Management believes existing cash supports operations for at least 12 months and expects to reach self-sustainability by end-2025 without equity financing, though that depends on product and royalty growth. Key near-term catalysts and risks include the March 23, 2025 PDUFA date for AMVUTTRA in ATTR cardiomyopathy following positive HELIOS-B data, the March 28, 2025 PDUFA for Sanofi's fitusiran, a July 2025 trial date in the Pfizer/BioNTech patent litigation, and a new University of Texas patent suit against ONPATTRO. Heavy reliance on collaborators, a 2023 FDA CRL for patisiran in ATTR-CM, and a Blackstone royalty step-up risk if Leqvio sales lag are also material.
Feb 13, 2025
2023
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2023
Alnylam Pharmaceuticals, Inc. (ALNY) reported its 2023 financial and operational results, showcasing significant revenue growth driven by its expanding portfolio of RNAi therapeutics. The company's net product revenues reached $1.24 billion, up 39% year-over-year, primarily due to the strong performance of AMVUTTRA and continued growth in GIVLAARI and OXLUMO, partially offset by a decline in ONPATTRO sales as patients transitioned to AMVUTTRA. Collaboration revenues also saw a substantial increase, largely from the new agreement with Roche for zilebesiran and increased royalties from Novartis on Leqvio. Alnylam continues to invest heavily in research and development, with expenses increasing by 14% to $1.0 billion, reflecting progress in its pipeline, including the development of zilebesiran for hypertension and ALN-APP for Alzheimer's disease. The company ended the year with $2.44 billion in cash, cash equivalents, and marketable securities, providing a solid liquidity position. Despite a net loss of $440 million, Alnylam is progressing towards its P5x25 strategic goals, aiming for profitability and a leading biotech profile by the end of 2025.
Feb 15, 2024
2022
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2022
Alnylam Pharmaceuticals, Inc. (ALNY) reported its 2022 financial and operational results in its Form 10-K filed on February 23, 2023. The company demonstrated significant growth in net product revenues, primarily driven by its ATTR amyloidosis franchise, with ONPATTRO and AMVUTTRA generating substantial revenue. The company is strategically advancing its pipeline with a focus on both rare and prevalent diseases, highlighted by progress in late-stage investigational programs. Financially, Alnylam ended 2022 with a strong cash position of $2.19 billion, supporting its operations and future development. The company also successfully raised $1.04 billion through convertible senior notes, with proceeds primarily used to repay existing debt. Alnylam remains committed to its P5x25 strategy, aiming to become a top-tier biotech company by 2025 through sustainable innovation and strong financial performance. Despite a reported net loss for the year, the company shows a positive trajectory with growing product revenues and a robust pipeline, positioning it for potential long-term value creation.
Feb 23, 2023
2021
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2021
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2021 performance, highlighting continued growth in its approved RNAi therapeutics portfolio with ONPATTRO, GIVLAARI, and OXLUMO. The company is advancing its "Alnylam P5x25" strategy, aiming to become a top five biotech company by 2025, with ambitious goals for patient reach, product launches, pipeline expansion, revenue growth, and profitability. Key developments include the FDA approval of Leqvio (inclisiran) for heterozygous familial hypercholesterolemia (HeFH) and clinical data for vutrisiran in ATTR amyloidosis, positioning it for potential regulatory approval. Financially, Alnylam ended 2021 with substantial cash reserves, but also reported an operating loss, reflecting ongoing investment in its pipeline and commercialization efforts. The company's strategic financing collaboration with Blackstone provided significant capital. Alnylam continues to navigate a competitive landscape and manages various risks, including those related to regulatory approvals, clinical trial outcomes, intellectual property, and market access.
Feb 10, 2022
2020
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2020
Alnylam Pharmaceuticals, Inc. (ALNY) reported its financial and operational highlights for the fiscal year ending December 31, 2020. The company, a leader in RNAi therapeutics, continues to advance its commercial-stage pipeline with four approved products: ONPATTRO®, GIVLAARI®, OXLUMO™, and Leqvio® (partnered with Novartis). Despite a net loss of $858.3 million for the year, the company demonstrated significant revenue growth, with total revenues reaching $492.9 million, a 124% increase year-over-year, driven by strong performance of ONPATTRO and GIVLAARI and the initial launch of OXLUMO. Key strategic advancements include progress on the APOLLO-B and HELIOS-B Phase 3 studies for ATTR amyloidosis with cardiomyopathy, positive topline results from the HELIOS-A Phase 3 study for vutrisiran, and the ongoing development of multiple early-stage pipeline candidates. Alnylam also secured a significant financing collaboration with Blackstone, providing up to $2 billion to support its growth initiatives, including the ambitious "Alnylam P5x25" strategy aimed at becoming a top five biotech company by market capitalization by the end of 2025. The company ended the year with a strong cash position of $1.87 billion, providing a solid foundation for future investments in research, development, and commercialization.
Feb 11, 2021
2019
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2019
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2019 Annual Report (10-K) on February 13, 2020, highlighting significant progress in its RNA interference (RNAi) therapeutics platform. The company achieved key milestones, including the U.S. FDA approval and launch of GIVLAARI for acute hepatic porphyria (AHP) and continued commercialization of ONPATTRO for hereditary transthyretin-mediated amyloidosis (hATTR) polyneuropathy, which generated $166.4 million in net revenue in 2019. Alnylam's "Alnylam 2020" strategy is on track, with a robust pipeline focused on four strategic therapeutic areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, Hepatic Infectious Diseases, and CNS/Ocular Diseases. Financially, the company ended 2019 with $1.55 billion in cash, cash equivalents, and marketable securities, positioning it to fund its operations and continued pipeline development. While the company reported a net loss of $886.1 million for the year, reflecting significant investment in R&D, it anticipates future growth driven by its expanding commercial product portfolio and promising late-stage pipeline candidates like lumasiran for primary hyperoxaluria type 1 (PH1). Strategic collaborations with major players like Regeneron and Sanofi Genzyme continue to be a cornerstone of Alnylam's development and commercialization strategy.
Feb 13, 2020
2018
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2018
Alnylam Pharmaceuticals reported its 2018 fiscal year results, marking a significant transition to a commercial-stage biopharmaceutical company with the launch of its first RNAi therapeutic, ONPATTRO®, in August 2018 for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis. The company generated $12.5 million in net revenue from ONPATTRO sales in 2018, with expansion into Europe occurring in the latter half of the year. Financially, Alnylam ended 2018 with strong liquidity, holding $1.13 billion in cash, cash equivalents, and marketable securities, bolstered by a $382 million public offering in January 2019. The company's pipeline remains robust, with five late-stage investigational programs advancing. These include vutrisiran for ATTR amyloidosis, givosiran for acute hepatic porphyria (AHP) where top-line Phase 3 data was positive, lumasiran for primary hyperoxaluria type 1, fitusiran for hemophilia (partnered with Sanofi Genzyme), and inclisiran for hypercholesterolemia (partnered with The Medicines Company). Alnylam's strategic restructuring of its alliance with Sanofi Genzyme in January 2018 clarified global rights for ONPATTRO and vutrisiran to Alnylam, and for fitusiran to Sanofi Genzyme, aligning with Alnylam's goal of building a multi-product commercial biopharmaceutical company.
Feb 14, 2019
2017
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2017
Alnylam Pharmaceuticals, Inc.'s 2017 10-K highlights a pivotal year marked by significant progress in its RNA interference (RNAi) therapeutic pipeline, particularly with patisiran. The company reached a major milestone by filing its first New Drug Application (NDA) with the FDA and a Marketing Authorisation Application (MAA) with the EMA for patisiran, targeting hereditary transthyretin-mediated (hATTR) amyloidosis. Regulatory reviews are underway with anticipated action dates in 2018, positioning Alnylam for potential product launch and revenue generation within the year. Financially, Alnylam strengthened its position by completing two public offerings that raised substantial net proceeds, ending the year with a robust cash balance. The company continues to invest heavily in research and development to advance its Alnylam 2020 strategy, aiming to have three marketed products and ten clinical-stage programs by the end of 2020. Key collaborations, notably with Sanofi Genzyme and The Medicines Company, remain central to its development and commercialization efforts, with recent amendments to the Sanofi Genzyme agreement significantly reshaping global rights for key pipeline assets.
Feb 15, 2018
2016
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2016
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2016 10-K, highlighting a significant focus on its RNA interference (RNAi) therapeutic platform. The company is advancing its "Alnylam 2020" strategy with the goal of becoming a multi-product commercial-stage biopharmaceutical company by the end of 2020, aiming for three marketed products and ten RNAi therapeutic clinical programs. The company's lead candidate, patisiran, for hereditary TTR-mediated amyloidosis (hATTR), is in Phase 3 development with top-line data expected mid-2017, and potential regulatory submissions planned for late 2017. Significant R&D investments continued in 2016, reflecting the advancement of a broad pipeline across three strategic therapeutic areas: Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases. The company also detailed progress in its manufacturing capabilities and global expansion, including its operational manufacturing facility for patisiran and construction of a new drug substance facility. Despite a substantial net loss of $410.1 million for 2016, driven by significant R&D expenses, Alnylam maintained a strong cash position of $942.6 million in cash, cash equivalents, and marketable securities at year-end, supported by strategic collaborations with companies like Sanofi Genzyme and The Medicines Company.
Feb 15, 2017
2015
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2015
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on RNA interference (RNAi). The company's strategy centers on its proprietary GalNAc-conjugate delivery platform for siRNAs, targeting genetically validated, liver-expressed genes. Alnylam has a pipeline across three Strategic Therapeutic Areas (STArs): Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases. The company has significant ongoing clinical development, with its most advanced program, patisiran for TTR-mediated amyloidosis (ATTR), in Phase 3 trials and expected to report data in 2017. Other key programs include revusiran (also for ATTR), fitusiran for hemophilia, and ALN-PCSsc for hypercholesterolemia. The company's financial performance is characterized by substantial R&D expenses and net losses, with revenues primarily driven by collaboration agreements. A substantial cash position and strategic alliances, particularly with Sanofi Genzyme, provide financial runway for continued development towards achieving its 'Alnylam 2020' goals.
Feb 12, 2016
2014
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2014
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. As of their February 13, 2015, 10-K filing, the company was in the clinical stage of development, with no products yet approved for commercial sale. Their primary strategy centers on using proprietary RNAi technology, particularly their GalNAc-conjugate delivery system, to create novel treatments for a range of diseases. The company has outlined an "Alnylam 2020" plan, aiming for three marketed products and ten clinical programs by the end of 2020. Key development areas include Genetic Medicines for rare diseases (with their most advanced program, patisiran, targeting transthyretin-mediated amyloidosis), Cardio-Metabolic Diseases (targeting conditions like hypercholesterolemia), and Hepatic Infectious Diseases (such as Hepatitis B). Significant recent events include a substantial public offering in January 2015, raising approximately $496.4 million in net proceeds, and a strategic collaboration with Genzyme announced in January 2014, which includes significant upfront payments and milestone potential. Financially, Alnylam reported substantial operating losses, consistent with its development-stage status, with an accumulated deficit of $956.6 million at the end of 2014. Despite ongoing losses, the company ended 2014 with a strong cash position of $881.9 million in cash, cash equivalents, and marketable securities, bolstered by the January 2015 public offering and the Genzyme collaboration, providing runway for continued investment in their robust pipeline.
Feb 13, 2015
2013
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2013
Alnylam Pharmaceuticals, Inc. (ALNY) reported its annual results for the fiscal year ending December 31, 2013. The company is a biopharmaceutical firm focused on developing RNA interference (RNAi) therapeutics, a novel class of medicines targeting genetic diseases. Key to Alnylam's strategy is its "Alnylam 5x15" program, aiming to have 6-7 genetic medicine candidates in clinical development, including at least two in Phase 3, by the end of 2015. The company's most advanced program, patisiran (ALN-TTR02), targets transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR) and has shown positive results in Phase 2 trials with initiation of a Phase 3 APOLLO trial. Significant recent developments include the planned acquisition of Sirna Therapeutics' RNAi assets from Merck and a major global strategic collaboration with Genzyme, a Sanofi company, for the development and commercialization of its genetic medicine pipeline outside of North America and Western Europe. This collaboration, including a $700 million equity investment from Genzyme, significantly strengthens Alnylam's financial position and provides substantial resources for advancing its pipeline. Financially, Alnylam reported net revenues from collaborators of $47.2 million, a decrease from $66.7 million in 2012, primarily due to the completion of certain collaboration obligations. Operating expenses were $140.1 million, a decrease from $196.2 million in 2012, mainly due to the absence of a significant restructuring charge incurred in the prior year, although R&D expenses increased to support pipeline advancement. The company reported a net loss of $89.2 million for 2013, compared to a net loss of $106.0 million in 2012. Alnylam ended the year with a strong cash position of $350.5 million, bolstered by its January 2013 public offering and the anticipated Genzyme investment, providing ample runway to fund its ongoing research and development activities.
Feb 20, 2014
2012
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2012
Alnylam Pharmaceuticals, Inc.'s 2012 10-K filing highlights a company in the early stages of developing novel RNA interference (RNAi) therapeutics. The company's core strategy, "Alnylam 5x15," aims to have five RNAi therapeutic programs in clinical development by the end of 2015. Financially, Alnylam reported a net loss of $106 million for 2012, continuing its trend of losses as it invests heavily in research and development. The company secured significant funding through a public offering in early 2013, raising approximately $173.6 million, which will be used to advance its clinical pipeline. Key partnerships with companies like The Medicines Company (MedCo) and Genzyme are crucial for developing and commercializing its product candidates in specific territories. The company emphasizes its strong intellectual property portfolio and its leading position in RNAi technology. Despite the significant risks associated with early-stage drug development and the competitive landscape, Alnylam appears to be strategically positioning itself for future growth by focusing on high unmet medical needs and leveraging its platform technology.
Feb 19, 2013
2011
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2011
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapeutics based on RNA interference (RNAi). In 2011, the company continued to advance its pipeline, with key programs like ALN-TTR for transthyretin-mediated amyloidosis (ATTR) and ALN-APC for hemophilia showing progress. The company reported preliminary Phase I data for ALN-TTR01 demonstrating dose-dependent reduction in serum TTR levels and for ALN-PCS showing significant silencing of PCSK9 protein levels and reductions in LDL-c. Financially, Alnylam continued to operate at a net loss, with significant investments in research and development. The company ended 2011 with a solid cash position of $260.8 million, supported by collaboration revenues primarily from Roche/Arrowhead and Takeda. However, total revenues decreased compared to the prior year, and the company implemented a strategic restructuring in early 2012, reducing its workforce by approximately 33% to focus resources on its highest-value opportunities. Significant legal proceedings related to intellectual property with Tekmira and other parties were ongoing, posing a potential risk to the company's operations and financial performance.
Feb 13, 2012
2010
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2010
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2010 annual report, highlighting its strategic focus on RNA interference (RNAi) therapeutics. The company is advancing its 'Alnylam 5x15' strategy, aiming to bring five RNAi therapeutic programs into advanced clinical development by the end of 2015. Alnylam is currently developing three core programs: ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. Financially, Alnylam reported net revenues from research collaborators of $100.0 million for 2010, with total operating expenses of $144.1 million, resulting in a net loss of $43.5 million. The company ended 2010 with $349.9 million in cash, cash equivalents, and marketable securities, indicating a strong cash position to fund ongoing research and development activities. Alnylam also emphasized its robust intellectual property portfolio and a strong base of strategic alliances with major pharmaceutical companies, which provide significant financial support and operational capabilities.
Feb 18, 2011
2009
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2009
Alnylam Pharmaceuticals (ALNY) enters 2010 as a clinical-stage RNAi therapeutics developer with no approved products and no product revenue. Its 2009 results show revenue of $100.5 million from research collaborators (up from $96.2 million), operating expenses of $148.6 million, and a net loss of $47.6 million, or $1.14 per share. Accumulated deficit stands at $299.8 million, and the company held $435.3 million in cash, cash equivalents and marketable securities at year-end. Roughly 57% of 2009 revenue came from Roche, with Takeda at 22% and Novartis at 10%, so revenue concentration is high. The pipeline is the main value driver. ALN-RSV01 for RSV has started a Phase IIb trial in lung transplant patients, with ALN-RSV02 in pediatric patients being co-developed with Cubist. ALN-VSP (liver cancer) is in Phase I, and ALN-TTR01 (ATTR) is expected to enter Phase I in the first half of 2010. ALN-PCS (hypercholesterolemia) was named the next clinical candidate. Novartis's integration option, a $100 million payment, could be a significant revenue event but is uncertain. Key risks include the unproven RNAi approach, reliance on collaborators for funding and commercialization, ongoing patent litigation with Whitehead, MIT and UMass (trial expected June 2010), and a cash burn that rose sharply in 2009 (operating cash flow of -$72.1 million). Management says current resources should fund planned operations for at least the next several years, though it may need additional capital sooner than expected.
Feb 26, 2010
2008
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2008
Alnylam Pharmaceuticals' FY2008 10-K, filed March 2, 2009, shows an RNAi-focused biopharma that narrowed its loss sharply on the back of large collaboration payments. Net revenues rose to $96.2 million in 2008 from $50.9 million in 2007, driven mainly by recognition of the August 2007 Roche alliance and the May 2008 Takeda alliance. Operating expenses fell 14% to $124.0 million, mainly because 2007 included $27.5 million of license fees tied to the Roche deal. The net loss narrowed to $26.2 million ($0.64 per share) from $85.5 million, and the company has never reported annual profitability. The balance sheet is strong for an early-stage company. Cash, cash equivalents and marketable securities totaled $512.7 million at year-end 2008, up from $455.6 million, while deferred revenue of $330.0 million (mostly Roche, Takeda and Kyowa Hakko) means much of that cash is tied to future obligations to deliver services rather than being free cash. Management states the existing cash plus expected alliance cash should fund operations for at least several years, though it warns of possible dilution and earlier funding needs. The pipeline is advancing but remains early. ALN-RSV01 (respiratory syncytial virus) is in Phase II, with a second trial started in April 2008 and new collaborations with Cubist (North America) and Kyowa Hakko (Asia) signed in 2008-2009. ALN-VSP, a systemically delivered liver cancer candidate, received FDA IND clearance in January 2009, with Phase I expected in the first half of 2009. Investors should weigh the company's dependence on a few collaborators (Roche, Takeda, Novartis), which together made up most 2008 revenue, and the unproven nature of RNAi therapeutics, against a large, exclusive-looking patent estate that is under opposition in Europe.
Mar 2, 2009
2007
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2007
Alnylam Pharmaceuticals' 2007 10-K (filed March 2008) shows a company transitioning from a pure research-stage RNAi developer toward a funded, alliance-driven pipeline. Net revenues rose to $50.9 million in 2007 from $26.9 million in 2006, driven largely by the August 2007 Roche alliance, which brought $331.0 million in upfront proceeds (of which $278.2 million is being recognized as revenue straight-line over five years). Despite the revenue increase, the company posted a net loss of $85.5 million (EPS of -$2.21) as operating expenses rose to $144.1 million, including $27.5 million in license fees paid largely to Isis tied to the Roche deal and $14.7 million in delivery-technology license charges. Accumulated deficit reached $226.0 million. Balance sheet strength improved markedly: cash, cash equivalents and marketable securities totaled $455.6 million at year-end 2007, versus $217.3 million a year earlier, and management states these resources, together with alliance cash, should fund planned operations for at least the next several years. Deferred revenue of $263.3 million is a large non-cash liability that will be recognized over coming years, so reported revenue will not fully reflect cash received. The key value driver is the lead program ALN-RSV01 for respiratory syncytial virus, which completed a Phase II GEMINI study in February 2008 showing approximately a 40% reduction in viral infection and a statistically significant anti-viral effect (p<0.01), with a second Phase II trial planned for 1H 2008. Investors should weigh this against the company's short operating history, lack of approved products, dependence on collaborators (Roche, Novartis, government contracts), concentrated revenue, and the unproven nature of RNAi as a drug class, along with ongoing European patent oppositions to its core Kreutzer-Limmer patent.
Mar 10, 2008
2006
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2006
Alnylam Pharmaceuticals (ALNY) reported its FY2006 10-K, filed March 2007, describing a clinical-stage biopharmaceutical company built around RNA interference (RNAi) therapeutics. Its lead program, ALN-RSV01 for respiratory syncytial virus, has been in Phase I trials since December 2005, with an inhaled formulation and a human challenge study added in late 2006. Other development programs cover pandemic flu (with Novartis) and hypercholesterolemia (ALN-PCS01, targeting PCSK9), alongside discovery programs in CNS disease, cystic fibrosis, PML and Ebola. The company remains unprofitable and has no approved products. Revenue is almost entirely collaboration-based, with Novartis contributing about 81% of 2006 revenue. Financially, 2006 net revenues rose to $26.9 million from $5.7 million, while the net loss narrowed slightly to $34.6 million from $42.9 million, helped by higher interest income. Operating expenses grew to $66.4 million, led by R&D of $49.8 million. The accumulated deficit reached $140.5 million. Liquidity improved substantially: cash, cash equivalents and marketable securities totaled $217.3 million at year-end, up from $80.0 million, after roughly $163 million of net proceeds from January and December 2006 follow-on offerings. Management states that existing resources plus expected collaboration cash should fund operations for at least several years. Key risks for investors include the unproven nature of RNAi as a drug class, dependence on Novartis (which holds about 14% of shares and has an option to integrate Alnylam's IP and compete), the Kreutzer-Limmer patent being challenged in European oppositions, and the reliance on government contracts such as the NIAID Ebola award. Future dilution from equity raises is a continuing concern.
Mar 12, 2007
2005
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2005
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2005 annual report, highlighting its pioneering work in RNA interference (RNAi) therapeutics. The company is focused on developing novel drugs that leverage the natural RNAi mechanism to selectively silence gene activity, addressing a broad range of diseases. ALNY's most advanced candidate, ALN-RSV01 for RSV infection, has entered Phase I clinical trials, with a pandemic flu therapeutic candidate expected to reach the IND stage by the end of 2006. The company's strategy centers on building a robust pipeline of proprietary RNAi therapeutics and forming strategic alliances with major pharmaceutical companies like Novartis and Merck. These collaborations are crucial for Alnylam's financial and operational growth, providing significant funding and development expertise. Alnylam has also secured a strong intellectual property portfolio, which it considers vital for its competitive advantage. Despite early-stage development and significant investment in research and development, Alnylam remains focused on its long-term vision of establishing RNAi therapeutics as a major drug class.
Mar 16, 2006
2004
ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2004
Alnylam Pharmaceuticals (ALNY) filed its FY2004 10-K on March 30, 2005, describing itself as an early-stage biopharmaceutical company built around RNA interference (RNAi), with a strategy of pursuing 'Direct RNAi' drugs for localized diseases (wet AMD, RSV, Parkinson's, spinal cord injury, cystic fibrosis) and later 'Systemic RNAi' therapeutics. The company has not yet commenced clinical trials for its lead candidates, which it expects to begin in 2H 2005 (AMD) and 1H 2006 (RSV). Financially, 2004 net revenues were $4.3 million (up from $0.2 million), against operating expenses of $36.5 million and a net loss of $32.7 million, or $2.98 per share. The accumulated deficit reached $63.0 million, and the company has never been profitable. Liquidity improved substantially in 2004 due to a June IPO (5.75 million shares at $6.00, net proceeds about $29.9 million), a $10 million Series D investment from Isis, and a $5 million equity purchase by Merck. Cash, cash equivalents and marketable securities totaled $46.0 million at year-end, and management believes existing resources will fund operations through at least the end of 2006. Against this, the company carries about $7.2 million drawn on a Lighthouse equipment line of credit, faces potential dilution from future financings, and depends heavily on collaborations with Merck, Isis, Medtronic and CFFT for funding. Key risks investors should weigh include the unproven nature of RNAi as a drug class (no siRNA therapeutic has been approved), the need to show siRNAs can be stable, non-immunogenic and delivered effectively, competition from Macugen, Lucentis, and two other siRNA VEGF programs at Acuity and Sirna, and patent uncertainty. In particular, two Kreutzer-Limmer patents face EPO and Australian opposition proceedings that could result in invalidation or narrowing. The company also reported that it was not party to material legal proceedings at filing.
Mar 30, 2005